Immuno-Oncology Add-On Trials: More May Not Be Better, US FDA Cautions

 
• By Michael McCaughan
  
immuno-oncology
It's not a principle that we have to repeat a mistake, Richard Pazdur said. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D